Patents by Inventor Lijian CAI

Lijian CAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20240158417
    Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
    Type: Application
    Filed: October 17, 2023
    Publication date: May 16, 2024
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO.,LTD.
    Inventors: Fusheng ZHOU, Tao JIANG, Chonglan LIN, Lijian CAI, Wan HE, Jiong LAN
  • FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
    Publication number: 20230203060
    Abstract: Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.
    Type: Application
    Filed: May 27, 2021
    Publication date: June 29, 2023
    Inventors: Fusheng ZHOU, Tao JIANG, Yingtao LIU, Jichen ZHAO, Wan HE, Zhubo LIU, Ling PENG, Lijian CAI, Leitao ZHANG, Chonglan LIN, Huabin YANG, Tao ZHANG, Jiong LAN
  • SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230084095
    Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
    Type: Application
    Filed: October 28, 2020
    Publication date: March 16, 2023
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Tao JIANG, Chonglan LIN, Lijian CAI, Wan HE, Jiong LAN
  • OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF
    Publication number: 20220251109
    Abstract: An oxaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or formula II, see the details of the definition to each group in the formulas in the specification), as well as the pharmaceutical composition containing the compound, and the application thereof in preparation of cancer medicine.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 11, 2022
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Lijian CAI, Tao JIANG, Jichen ZHAO, Yingtao LIU, Jinzhu ZHAO, Leitao ZHANG, Zhubo LIU, Ling PENG, Wan HE, Huabin YANG, Tao ZHANG, Qian DING, Biao ZHENG, Qiang LV, Jiong LAN